Table 3.
The biochemical response of DAAs treatment.
| All (n = 54) | CHC (n = 39) | CIR (n = 15) | Statistics | p | |
|---|---|---|---|---|---|
| ALT0 (IU/L) | 91.6 ± 68.0 | 99.6 ± 75.6 | 70.0 ± 35.1 | 1.841 | 0.072 |
| Baseline ALT abnormality | 36 (66.7%) | 26 (66.7%) | 10 (66.7%) | 0.000 | 1.000 |
| ALT normality | |||||
| W4 | 44 (81.5%) | 35 (89.7%) | 9 (60.0%) | 4.533 | 0.033 |
| W12 | 49 (90.7%) | 36 (92.3%) | 13 (86.7%) | 0.014 | 0.907 |
| EOT | 48 (88.9%) | 36 (92.3%) | 12 (80.0%) | 0.649 | 0.420 |
| F12 | 47 (87.0%) | 37 (94.9%) | 10 (66.7%) | 5.343 | 0.021 |
| TBil0 (μmol/L) | 13.8 ± 7.4 | 11.2 ± 4.6 | 20.3 ± 9.4 | 3.306 | 0.005 |
| ΔTB4_0 | 1.1 ± 5.0 | 1.1 ± 4.6 | 1.3 ± 5.9 | 0.154 | 0.878 |
| ΔTB12_0 | −0.6 ± 6.1 | −0.4 ± 4.2 | −1.1 ± 9.2 | 0.238 | 0.815 |
| ΔTB_EOT_0 | −1.4 ± 4.5 | −1.3 ± 3.6 | −1.9 ± 6.2 | 0.334 | 0.743 |
| ΔTB_F12_0 | −2.4 ± 6.6 | −3.4 ± 5.0 | 0.2 ± 9.5 | 1.124 | 0.285 |
| eGFR0 (ml/min.1.73 m2) | 107.3 ± 19.0 | 107.0 ± 21.8 | 108.3 ± 9.8 | 0.162 | 0.872 |
| ΔeGFR4_0 | 2.4 ± 11.1 | 4.6 ± 12.8 | −2.2 ± 4.7 | 1.445 | 0.163 |
| ΔeGFR12_0 | 0.5 ± 11.3 | 1.6 ± 12.8 | −1.9 ± 7.1 | 0.903 | 0.372 |
| ΔeGFR_EOT_0 | 2.3 ± 11.9 | 2.8 ± 13.6 | 1.3 ± 7.1 | 0.324 | 0.748 |
| ΔeGFR_F12_0 | 0.0 ± 12.4 | −0.8 ± 13.9 | 1.6 ± 8.9 | 0.503 | 0.618 |
CHC: chronic hepatitis C; CIR: cirrhosis; BMI: body mass index; ALT: alanine aminotransferase; TBil: total bilirubin; eGFR: estimated glomerular filtration rate; W4: week 4 of treatment; W12: week 12 of treatment; EOT: end of treatment; F12: 12 weeks after end of treatment; ALT0: ALT at baseline (same for TBil0 and eGFR0); ΔTB4_0 or ΔeGFR4_0: changes of TBil or eGFR from baseline to week 4 (TB4–TB0, or eGFR4–eGFR0); ΔTB12_0 or ΔeGFR12_0: changes of TBil or eGFR from baseline to week 12; ΔTB_EOT_0 or ΔeGFR_EOT_0: changes of TBil or eGFR from baseline to end of treatment; ΔTB_F12_0 or ΔeGFR_F12_0: changes of TBil or eGFR from baseline to 12 weeks after end of treatment.